Need help finding what you are looking for?
Contact Us
PUBLISHER: Transparency Market Research | PRODUCT CODE: 1229560
PUBLISHER: Transparency Market Research | PRODUCT CODE: 1229560
Gene Vector Market (Vector Type: Lentivirus, Adenovirus, Adeno-associated Virus, Plasmid DNA, & Others, Disease: Genetic Disorder, Cancer, Infectious Disease, & Others) - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast, 2022-2031
PUBLISHED:
PAGES: 190 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
The report provides revenue of the global gene vector market for the period 2017-2031, considering 2022 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global gene vector market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the gene vector market.
The report delves into the competitive landscape of the global gene vector market. Key players operating in the global gene vector market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global gene vector market profiled in this report.
Product Code: TMRGL85337
Table of Contents
1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gene Vector Market
4. Market Overview
- 4.1. Introduction
- 4.1.1. Definition
- 4.1.2. Industry Evolution/Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Gene Vector Market Analysis and Forecasts, 2017 - 2031
- 4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
- 5.1. Technological Advancements
- 5.2. Major Research Institutes Involved
- 5.3. Disease Prevalence & Incidence Rate globally with key countries
- 5.4. COVID-19 Pandemic Impact on Industry
6. Global Gene Vector Market Analysis and Forecast, by Vector Type
- 6.1. Introduction & Definition
- 6.2. Key Findings / Developments
- 6.3. Market Value Forecast, by Vector Type, 2017 - 2031
- 6.3.1. Lentivirus
- 6.3.2. Adenovirus
- 6.3.3. Adeno-associated Virus (AAV)
- 6.3.4. Plasmid DNA
- 6.3.5. Others
- 6.4. Market Attractiveness, by Vector Type
7. Global Gene Vector Market Analysis and Forecast, by Application
- 7.1. Introduction & Definition
- 7.2. Key Findings / Developments
- 7.3. Market Value Forecast, by Application, 2017 - 2031
- 7.3.1. Gene Therapy
- 7.3.2. Vaccinology
- 7.3.3. Others
- 7.4. Market Attractiveness, by Application
8. Global Gene Vector Market Analysis and Forecast, by Disease
- 8.1. Introduction & Definition
- 8.2. Key Findings / Developments
- 8.3. Market Value Forecast, by Disease, 2017 - 2031
- 8.3.1. Genetic Disorder
- 8.3.2. Cancer
- 8.3.3. Infectious Disease
- 8.3.4. Others
- 8.4. Market Attractiveness, by Disease
9. Global Gene Vector Market Analysis and Forecast, by End-user
- 9.1. Introduction & Definition
- 9.2. Key Findings / Developments
- 9.3. Market Value Forecast, by End-user, 2017 - 2031
- 9.3.1. Scientific Research
- 9.3.2. CRO
- 9.3.3. CDMO
- 9.3.4. Others (Pharmaceutical, Biotechnology Companies)
- 9.4. Market Attractiveness, by End-user
10. Global Gene Vector Market Analysis and Forecast, by Region
- 10.1. Key Findings
- 10.2. Market Value Forecast, by Region
- 10.2.1. North America
- 10.2.2. Europe
- 10.2.3. Asia Pacific
- 10.2.4. Latin America
- 10.2.5. Middle East & Africa
- 10.3. Market Attractiveness, by Country/Region
11. North America Gene Vector Market Analysis and Forecast
- 11.1. Introduction
- 11.1.1. Key Findings
- 11.2. Market Value Forecast, by Vector Type, 2017 - 2031
- 11.2.1. Lentivirus
- 11.2.2. Adenovirus
- 11.2.3. Adeno-associated Virus (AAV)
- 11.2.4. Plasmid DNA
- 11.2.5. Others
- 11.3. Market Value Forecast, by Application, 2017 - 2031
- 11.3.1. Gene Therapy
- 11.3.2. Vaccinology
- 11.3.3. Others
- 11.4. Market Value Forecast, by Disease, 2017 - 2031
- 11.4.1. Genetic Disorder
- 11.4.2. Cancer
- 11.4.3. Infectious Disease
- 11.4.4. Others
- 11.5. Market Value Forecast, by End-user, 2017 - 2031
- 11.5.1. Scientific Research
- 11.5.2. CRO
- 11.5.3. CDMO
- 11.5.4. Others (Pharmaceutical, Biotechnology Companies)
- 11.6. Market Value Forecast, by Country, 2017 - 2031
- 11.6.1. U.S.
- 11.6.2. Canada
- 11.7. Market Attractiveness Analysis
- 11.7.1. By Vector Type
- 11.7.2. By Application
- 11.7.3. By Disease
- 11.7.4. By End-user
- 11.7.5. By Country
12. Europe Gene Vector Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Key Findings
- 12.2. Market Value Forecast, by Vector Type, 2017 - 2031
- 12.2.1. Lentivirus
- 12.2.2. Adenovirus
- 12.2.3. Adeno-associated Virus (AAV)
- 12.2.4. Plasmid DNA
- 12.2.5. Others
- 12.3. Market Value Forecast, by Application, 2017 - 2031
- 12.3.1. Gene Therapy
- 12.3.2. Vaccinology
- 12.3.3. Others
- 12.4. Market Value Forecast, by Disease, 2017 - 2031
- 12.4.1. Genetic Disorder
- 12.4.2. Cancer
- 12.4.3. Infectious Disease
- 12.4.4. Others
- 12.5. Market Value Forecast, by End-user, 2017 - 2031
- 12.5.1. Scientific Research
- 12.5.2. CRO
- 12.5.3. CDMO
- 12.5.4. Others (Pharmaceutical, Biotechnology Companies)
- 12.6. Market Value Forecast, by Country, 2017 - 2031
- 12.6.1. Germany
- 12.6.2. U.K.
- 12.6.3. France
- 12.6.4. Spain
- 12.6.5. Italy
- 12.6.6. Rest of Europe
- 12.7. Market Attractiveness Analysis
- 12.7.1. By Vector Type
- 12.7.2. By Application
- 12.7.3. By Disease
- 12.7.4. By End-user
- 12.7.5. By Country
13. Asia Pacific Gene Vector Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Key Findings
- 13.2. Market Value Forecast, by Vector Type, 2017 - 2031
- 13.2.1. Lentivirus
- 13.2.2. Adenovirus
- 13.2.3. Adeno-associated Virus (AAV)
- 13.2.4. Plasmid DNA
- 13.2.5. Others
- 13.3. Market Value Forecast, by Application, 2017 - 2031
- 13.3.1. Gene Therapy
- 13.3.2. Vaccinology
- 13.3.3. Others
- 13.4. Market Value Forecast, by Disease, 2017 - 2031
- 13.4.1. Genetic Disorder
- 13.4.2. Cancer
- 13.4.3. Infectious Disease
- 13.4.4. Others
- 13.5. Market Value Forecast, by End-user, 2017 - 2031
- 13.5.1. Scientific Research
- 13.5.2. CRO
- 13.5.3. CDMO
- 13.5.4. Others (Pharmaceutical, Biotechnology Companies)
- 13.6. Market Value Forecast, by Country, 2017 - 2031
- 13.6.1. China
- 13.6.2. Japan
- 13.6.3. India
- 13.6.4. Australia & New Zealand
- 13.6.5. Rest of Asia Pacific
- 13.7. Market Attractiveness Analysis
- 13.7.1. By Vector Type
- 13.7.2. By Application
- 13.7.3. By Disease
- 13.7.4. By End-user
- 13.7.5. By Country
14. Latin America Gene Vector Market Analysis and Forecast
- 14.1. Introduction
- 14.1.1. Key Findings
- 14.2. Market Value Forecast, by Vector Type, 2017 - 2031
- 14.2.1. Lentivirus
- 14.2.2. Adenovirus
- 14.2.3. Adeno-associated Virus (AAV)
- 14.2.4. Plasmid DNA
- 14.2.5. Others
- 14.3. Market Value Forecast, by Application, 2017 - 2031
- 14.3.1. Gene Therapy
- 14.3.2. Vaccinology
- 14.3.3. Others
- 14.4. Market Value Forecast, by Disease, 2017 - 2031
- 14.4.1. Genetic Disorder
- 14.4.2. Cancer
- 14.4.3. Infectious Disease
- 14.4.4. Others
- 14.5. Market Value Forecast, by End-user, 2017 - 2031
- 14.5.1. Scientific Research
- 14.5.2. CRO
- 14.5.3. CDMO
- 14.5.4. Others (Pharmaceutical, Biotechnology Companies)
- 14.6. Market Value Forecast, by Country, 2017 - 2031
- 14.6.1. Brazil
- 14.6.2. Mexico
- 14.6.3. Rest of Latin America
- 14.7. Market Attractiveness Analysis
- 14.7.1. By Vector Type
- 14.7.2. By Application
- 14.7.3. By Disease
- 14.7.4. By End-user
- 14.7.5. By Country
15. Middle East & Africa Gene Vector Market Analysis and Forecast
- 15.1. Introduction
- 15.1.1. Key Findings
- 15.2. Market Value Forecast, by Vector Type, 2017 - 2031
- 15.2.1. Lentivirus
- 15.2.2. Adenovirus
- 15.2.3. Adeno-associated Virus (AAV)
- 15.2.4. Plasmid DNA
- 15.2.5. Others
- 15.3. Market Value Forecast, by Application, 2017 - 2031
- 15.3.1. Gene Therapy
- 15.3.2. Vaccinology
- 15.3.3. Others
- 15.4. Market Value Forecast, by Disease, 2017 - 2031
- 15.4.1. Genetic Disorder
- 15.4.2. Cancer
- 15.4.3. Infectious Disease
- 15.4.4. Others
- 15.5. Market Value Forecast, by End-user, 2017 - 2031
- 15.5.1. Scientific Research
- 15.5.2. CRO
- 15.5.3. CDMO
- 15.5.4. Others (Pharmaceutical, Biotechnology Companies)
- 15.6. Market Value Forecast, by Country, 2017 - 2031
- 15.6.1. GCC Countries
- 15.6.2. South Africa
- 15.6.3. Rest of Middle East & Africa
- 15.7. Market Attractiveness Analysis
- 15.7.1. By Vector Type
- 15.7.2. By Application
- 15.7.3. By Disease
- 15.7.4. By End-user
- 15.7.5. By Country
16. Competition Landscape
- 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
- 16.2. Market Share Analysis By Company (2021)
- 16.3. Company Profiles
- 16.3.1. Lonza
- 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.1.2. Product Portfolio
- 16.3.1.3. Financial Overview
- 16.3.1.4. SWOT Analysis
- 16.3.1.5. Strategic Overview
- 16.3.2. Merck KGaA
- 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.2.2. Product Portfolio
- 16.3.2.3. Financial Overview
- 16.3.2.4. SWOT Analysis
- 16.3.2.5. Strategic Overview
- 16.3.3. Oxford Biomedica
- 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.3.2. Product Portfolio
- 16.3.3.3. Financial Overview
- 16.3.3.4. SWOT Analysis
- 16.3.3.5. Strategic Overview
- 16.3.4. CGT Catapult
- 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.4.2. Product Portfolio
- 16.3.4.3. Financial Overview
- 16.3.4.4. SWOT Analysis
- 16.3.4.5. Strategic Overview
- 16.3.5. Charles River Laboratories
- 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.5.2. Product Portfolio
- 16.3.5.3. Financial Overview
- 16.3.5.4. SWOT Analysis
- 16.3.5.5. Strategic Overview
- 16.3.6. uniQure N.V.
- 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.6.2. Product Portfolio
- 16.3.6.3. Financial Overview
- 16.3.6.4. SWOT Analysis
- 16.3.6.5. Strategic Overview
- 16.3.7. FUJIFILM Diosynth Biotechnologies
- 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.7.2. Product Portfolio
- 16.3.7.3. Financial Overview
- 16.3.7.4. SWOT Analysis
- 16.3.7.5. Strategic Overview
- 16.3.8. Spark Therapeutics, Inc.
- 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 16.3.8.2. Product Portfolio
- 16.3.8.3. Financial Overview
- 16.3.8.4. SWOT Analysis
- 16.3.8.5. Strategic Overview
- 16.3.9. Other Prominent Players
- 16.3.1. Lonza
Product Code: TMRGL85337
List of Tables
- Table 01: Global Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017-2031
- Table 02: Global Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017-2031
- Table 03: Global Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017-2031
- Table 04: Global Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017-2031
- Table 05: Global Gene Vector Market Value (US$ Mn) Forecast, by Region, 2017-2031
- Table 06: North America Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017-2031
- Table 07: North America Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017-2031
- Table 08: North America Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017-2031
- Table 09: North America Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017-2031
- Table 10: North America Gene Vector Market Value (US$ Mn) Forecast, by Country, 2017-2031
- Table 11: Europe Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017-2031
- Table 12: Europe Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017-2031
- Table 13: Europe Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017-2031
- Table 14: Europe Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017-2031
- Table 15: Europe Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
- Table 16: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017-2031
- Table 17: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017-2031
- Table 18: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017-2031
- Table 19: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017-2031
- Table 20: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
- Table 21: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017-2031
- Table 22: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017-2031
- Table 23: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017-2031
- Table 24: Latin America Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017-2031
- Table 25: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
- Table 26: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017-2031
- Table 27: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017-2031
- Table 28: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017-2031
- Table 29: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017-2031
- Table 30: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
List of Figures
- Figure 01: Global Gene Vector Market Value (US$ Mn) Forecast, 2017-2031
- Figure 02: Global Gene Vector Market Value Share Analysis, by Vector Type, 2021 and 2031
- Figure 03: Global Gene Vector Market Attractiveness Analysis, by Vector Type, 2022-2031
- Figure 04: Global Gene Vector Market Value Share Analysis, by Application, 2021 and 2031
- Figure 05: Global Gene Vector Market Attractiveness Analysis, by Application, 2022-2031
- Figure 06: Global Gene Vector Market Value Share Analysis, by Disease, 2021 and 2031
- Figure 07: Global Gene Vector Market Attractiveness Analysis, by Disease, 2022-2031
- Figure 08: Global Gene Vector Market Value Share Analysis, by End-user, 2021 and 2031
- Figure 09: Global Gene Vector Market Attractiveness Analysis, by End-user, 2022-2031
- Figure 10: Global Gene Vector Market Value Share Analysis, by Region, 2021 and 2031
- Figure 11: Global Gene Vector Market Attractiveness Analysis, by Region, 2022-2031
- Figure 12: North America Gene Vector Market Value (US$ Mn) Forecast, 2017-2031
- Figure 13: North America Gene Vector Market Value Share Analysis, by Vector Type, 2021 and 2031
- Figure 14: North America Gene Vector Market Attractiveness Analysis, by Vector Type, 2022-2031
- Figure 15: North America Gene Vector Market Value Share Analysis, by Application, 2021 and 2031
- Figure 16: North America Gene Vector Market Attractiveness Analysis, by Application, 2022-2031
- Figure 17: North America Gene Vector Market Value Share Analysis, by Disease, 2021 and 2031
- Figure 18: North America Gene Vector Market Attractiveness Analysis, by Disease, 2022-2031
- Figure 19: North America Gene Vector Market Value Share Analysis, by End-user, 2021 and 2031
- Figure 20: North America Gene Vector Market Attractiveness Analysis, by End-user, 2022-2031
- Figure 21: North America Gene Vector Market Value Share Analysis, by Country, 2021 and 2031
- Figure 22: North America Gene Vector Market Attractiveness Analysis, by Country, 2022-2031
- Figure 23: Europe Gene Vector Market Value (US$ Mn) Forecast, 2017-2031
- Figure 24: Europe Gene Vector Market Value Share Analysis, by Vector Type, 2021 and 2031
- Figure 25: Europe Gene Vector Market Attractiveness Analysis, by Vector Type, 2022-2031
- Figure 26: Europe Gene Vector Market Value Share Analysis, by Application, 2021 and 2031
- Figure 27: Europe Gene Vector Market Attractiveness Analysis, by Application, 2022-2031
- Figure 28: Europe Gene Vector Market Value Share Analysis, by Disease, 2021 and 2031
- Figure 29: Europe Gene Vector Market Attractiveness Analysis, by Disease, 2022-2031
- Figure 30: Europe Gene Vector Market Value Share Analysis, by End-user, 2021 and 2031
- Figure 31: Europe Gene Vector Market Attractiveness Analysis, by End-user, 2022-2031
- Figure 32: Europe Gene Vector Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
- Figure 33: Europe Gene Vector Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
- Figure 34: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, 2017-2031
- Figure 35: Asia Pacific Gene Vector Market Value Share Analysis, by Vector Type, 2021 and 2031
- Figure 36: Asia Pacific Gene Vector Market Attractiveness Analysis, by Vector Type, 2022-2031
- Figure 37: Asia Pacific Gene Vector Market Value Share Analysis, by Application, 2021 and 2031
- Figure 38: Asia Pacific Gene Vector Market Attractiveness Analysis, by Application, 2022-2031
- Figure 39: Asia Pacific Gene Vector Market Value Share Analysis, by Disease, 2021 and 2031
- Figure 40: Asia Pacific Gene Vector Market Attractiveness Analysis, by Disease, 2022-2031
- Figure 41: Asia Pacific Gene Vector Market Value Share Analysis, by End-user, 2021 and 2031
- Figure 42: Asia Pacific Gene Vector Market Attractiveness Analysis, by End-user, 2022-2031
- Figure 43: Asia Pacific Gene Vector Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
- Figure 44: Asia Pacific Gene Vector Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
- Figure 45: Latin America Gene Vector Market Value (US$ Mn) Forecast, 2017-2031
- Figure 46: Latin America Gene Vector Market Value Share Analysis, by Vector Type, 2021 and 2031
- Figure 47: Latin America Gene Vector Market Attractiveness Analysis, by Vector Type, 2022-2031
- Figure 48: Latin America Gene Vector Market Value Share Analysis, by Application, 2021 and 2031
- Figure 49: Latin America Gene Vector Market Attractiveness Analysis, by Application, 2022-2031
- Figure 50: Latin America Gene Vector Market Value Share Analysis, by Disease, 2021 and 2031
- Figure 51: Latin America Gene Vector Market Attractiveness Analysis, by Disease, 2022-2031
- Figure 52: Latin America Gene Vector Market Value Share Analysis, by End-user, 2021 and 2031
- Figure 53: Latin America Gene Vector Market Attractiveness Analysis, by End-user, 2022-2031
- Figure 54: Latin America Gene Vector Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
- Figure 55: Latin America Gene Vector Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
- Figure 56: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, 2017-2031
- Figure 57: Middle East & Africa Gene Vector Market Value Share Analysis, by Vector Type, 2021 and 2031
- Figure 58: Middle East & Africa Gene Vector Market Attractiveness Analysis, by Vector Type, 2022-2031
- Figure 59: Middle East & Africa Gene Vector Market Value Share Analysis, by Application, 2021 and 2031
- Figure 60: Middle East & Africa Gene Vector Market Attractiveness Analysis, by Application, 2022-2031
- Figure 61: Middle East & Africa Gene Vector Market Value Share Analysis, by Disease, 2021 and 2031
- Figure 62: Middle East & Africa Gene Vector Market Attractiveness Analysis, by Disease, 2022-2031
- Figure 63: Middle East & Africa Gene Vector Market Value Share Analysis, by End-user, 2021 and 2031
- Figure 64: Middle East & Africa Gene Vector Market Attractiveness Analysis, by End-user, 2022-2031
- Figure 65: Middle East & Africa Gene Vector Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
- Figure 66: Middle East & Africa Gene Vector Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
- Figure 67: Global Gene Vector Market Share Analysis, by Company, 2021
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.